At Stem Cells Transplant Institute, we offer stem cell therapy for rheumatoid arthritis to help reduce inflammation, support joint health, and improve long-term mobility through regenerative treatment.
Rheumatoid arthritis is a chronic autoimmune disease in which the immune system attacks the lining of the joints, leading to inflammation in the synovial membrane and causing swelling, pain, and progressive joint damage. As the tendons and ligaments supporting the joints become damaged, the joint may lose stability, and symptoms can extend beyond the joints to other organ systems.
The exact cause of RA remains under investigation. According to global estimates, nearly 18 million people worldwide live with rheumatoid arthritis — roughly 0.2 % of the global population, and about 0.5 – 1 % of adults in many regions.
Because RA is driven by immune dysregulation, effective long-term management is typically required, and structural joint damage is often irreversible once established.
Stem cell therapy for Rheumatoid Arthritis is offered at the Stem Cells Transplant Institute located in San José, Costa Rica, as a complement to ongoing rheumatologic care. Treatment is delivered within a certified clinical facility under physician supervision, with protocols designed to integrate with existing medical management.
Patients from the United States, Canada, and Europe travel to San José to access physician-supervised regenerative medicine programs delivered within structured clinical environments, particularly when disease activity persists despite multiple treatment adjustments. Costa Rica offers access to MSC protocols at costs that reflect what most patients can realistically afford.
Before scheduling therapy and to determine candidacy, all patients undergo a comprehensive medical review which includes coordination with the patient’s treating rheumatologist and typically involves: current biologic or DMARD regimen, recent inflammatory markers, and joint involvement. Our team works with the patient’s rheumatologist on medication timing around the treatment visit.
RA involves chronic inflammation and immune system overactivity. Research suggests that mesenchymal stem cells (MSCs) may help support joint health by modulating inflammatory activity, regulating immune responses, promoting a healthier synovial environment, and releasing growth factors that support tissue homeostasis.
MSC therapy does not replace existing RA medications, but it may serve as a supportive option aimed at improving comfort, mobility, and overall joint function.
(Evidence remains preliminary, and ongoing controlled clinical trials are required to confirm the magnitude and consistency of these effects.)
MSCs help regulate overactive immune cells involved in RA-related inflammation, contributing to a more balanced immune response.
(Wang et al., 2020)
MSCs release IL-10 and other immunomodulatory proteins that may help reduce inflammatory activity in affected joints.
(Li et al., 2022)
MSC-derived growth factors may help support the health of cartilage and synovial tissue by modulating the local microenvironment and promoting anti-inflammatory conditions.
(Romani et al., 2021)
MSCs may support improved vascular and tissue function around inflamed joints, contributing to a more stable joint microenvironment over time.
(Wang et al., 2020)
Although individual responses vary widely, published studies and clinical observations have reported potential supportive improvement in the following functional domains:
*These percentages summarizes ranges reported in selected clinical studies and observational cohorts under controlled conditions and standardized outcomes measures. They are not specific to any single study or to treatments performed at Stem Cells Transplant Institute. They should not be interpreted as averages, promises, or guaranteed results for individual patients. Evidence for MSC therapy in rheumatoid arthritis remains preliminary, and ongoing controlled clinical trials are still evaluating the magnitude, durability and consistency of these effects. All observations should be considered exploratory and hypothesis-generating rather than definitive proof of efficacy.
Published studies and patient-reported outcomes suggest that improvements after mesenchymal stem cell (MSC) therapy for RA may develop gradually over time. These timelines are illustrative summaries rather than predictions, and individual responses vary significantly.
*These timelines summarize patterns reported across selected published studies and observational cohorts. They are not specific predictions, and they do not represent expected outcomes for any individual patient. Individual experiences vary considerably, and some patients may experience minimal or no improvement. Evidence for MSC therapy in RA remains preliminary, and larger controlled clinical trials are needed to validate these observations. All timelines should be interpreted as exploratory and non-confirmatory.
No. MSC therapy for rheumatoid arthritis is not FDA-approved. In Costa Rica, it is offered under country’s regulatory framework for regenerative medicine. Clinical research is ongoing worldwide to evaluate its safety and effectiveness.
Yes. Most patients continue their prescribed RA medications. Any adjustments should be made only by your rheumatologist, who can evaluate whether changes are appropriate based on your individual clinical situation.
You can request a personalized cost estimate online. The final price is determined after our medical team reviews your medical history, current medications, and disease progression.
Rheumatoid Arthritis varies widely between individuals, so evaluating your case first ensures that the recommended therapy — and its cost — is accurate and medically appropriate.
MSC therapy is generally well tolerated. Some patients may experience temporary effects such as fatigue, headache, or low-grade fever may occur. Serious side effects are rare but remain possible with any medical procedure. Every patient undergoes medical evaluation to determine whether the therapy is appropriate and to help reduce potential risks. Emergency support is available on-site if needed.
No. MSC therapy does not cure rheumatoid arthritis, and it does not stop the underlying autoimmune process. The therapy may help support joint function and modulate inflammation, but RA remains a chronic condition that requires long-term medical management.
Phase I/IIa clinical trial evaluating safety and therapeutic outcomes of autologous adipose-derived mesenchymal stem cell therapy in rheumatoid arthritis patients.
View published study
Scientific review explaining immunomodulatory mechanisms and therapeutic effects of mesenchymal stem cells in rheumatoid arthritis.
View published study
Research review exploring emerging stem cell–based therapeutic strategies and future treatment perspectives for rheumatoid arthritis.
View published study
San José, Costa Rica
info@stemcellstransplantinstitute.com
+1 888 785-4170
